These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Production of binding proteins and role of the insulin-like growth factor I binding protein 3 in human articular cartilage explants.
    Author: Chevalier X, Tyler JA.
    Journal: Br J Rheumatol; 1996 Jun; 35(6):515-22. PubMed ID: 8670570.
    Abstract:
    The aim of this study was to determine the production of insulin-like growth factor binding proteins (IGFBP) and the role of the IGFBP-3 in human normal (n = 2) and osteoarthritic (OA) articular cartilage (n = 14) explants. Binding proteins were studied in the medium by Western ligand blotting and Western blotting. Proteoglycan synthesis under insulin-like growth factor I (IGF-I) stimulation was studied after a pulse of 35SO4(2-) in the presence or absence of added IGFBP-3. Osteoarthritic explants released a doublet of IGFBPs with a 39/43 kDa Mr corresponding to the binding protein 3. Constitutive production from unstimulated OA cartilage was higher than from normal cartilage. IGF-I induced a 20-fold increase and IL-1 a 2-fold increase in IGFBP-3 release. A minor band around 30 kDa was also detectable. Studies of proteoglycan (PG) synthesis showed that the majority of OA cartilage explant samples responded weakly to IGF-I (100 ng/ml) stimulation (+33%), while the others were high responders (+180%). Co-incubation of IGF-I with recombinant (r) IGFBP-3 did not affect the rate of PG synthesis. However, while pre-incubation with rIGFBP3 for 72 h did not change the rate of PG synthesis in the high-responder group, it strongly increased PG synthesis in the low-responder group. This study demonstrates that the ability of IGF-I to enhance proteoglycan synthesis varied among the OA samples and may in part be dependent on the local level of IGFBP-3. This implies pathophysiological considerations in the limits of IGF-I action during the OA process.
    [Abstract] [Full Text] [Related] [New Search]